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Abstract. Renal cell carcinomas (RCC) can be subclassified
for general purposes into clear cell, papillary cell, chromo-
phobe cell carcinomas and oncocytomas. Other tumours such
as collecting duct, medullary, mucinous tubular and spindle
cell and associated with Xp 11.2 translocations/TFE 3 gene
fusion, are much less common. There is also a residual group
of unclassified cases. Previous studies have shown that RCC
has high glycolytic rates, and expresses GLUT transporters,
but no distinction has been made among the different sub-
types of renal cell tumours and their grades of malignancy. In
clear renal cell carcinoma (cRCC) glycogen levels increase,
glycolysis is activated and gluconeogenesis is reduced. The
clear cell subtype of RCC is characterized histologically by
a distinctive pale, glassy cytoplasm and this appearance of
cRCC is due to abnormalities in carbohydrate and lipid
metabolism, and this abnormality results in glycogen and sterol
storage. Several isoforms of glucose carriers (GLUTs) have
been identified. We show here in a panel of 80 cRCC samples
a significant correlation between isoform 5 (GLUT5) and many
pathological parameters such as grade of differentiation,
pelvis invasion and breaking capsule. GLUT5 expression
also appears to associate more strongly with the clear cell
RCC subtype. These data suggest a role for the GLUT5
isoform in fructose uptake that takes place in cRCC cells and
which subsequently leads to the malignant RCC progression.
Introduction
Glucose is a major source of metabolic energy and virtually
all animal cells possess a transporter system for glucose of
the facilitative diffusion type.
Glucose influx across the membrane cells is mediated by
glucose transporters (GLUTs) which have at least 12 isoforms
(1). The facilitative GLUTs use existing gradients in glucose
(and other hexoses/polyols) concentration between the external
and internal faces of a membrane to facilitate their trans-
location, thus ensuring a continuous supply of glucose to most
tissues. These transporters are the products of distinct genes
and exhibit considerable homology in their primary sequences
but display a marked tissue-specific pattern of expression: the
GLUT isoforms have different tissue distribution, function
and developmental regulation. So far, different complementary
DNAs (cDNAs) encoding these different species have been
isolated (2-12), which have been named GLUT1 (expressed
in all tissues and specially abundant in erythrocytes and brain),
GLUT2 (present in liver, pancreatic islet ß cell, kidney and at
the basolateral surface of the absorptive cells of the small
intestine), GLUT3 (abundant in brain), GLUT4 (restricted to
adipose, heart and skeletal tissues) and GLUT5 (expressed in
small intestine, sperm cells and kidney) (Table I) (Fig. 1)
Laboratory in vitro and in vivo expression systems have
demonstrated that these transporters not only function as
glucose transporters but are also capable of transporting other
sugars.
Among the GLUTs family members able to transport
fructose, GLUT5 is the sole transporter specific for fructose
with no ability to transport glucose or galactose (13).
The second major fructose transporter is GLUT2, a low-
affinity transporter that is also capable of recognizing glucose
and galactose. GLUT2 in a bidirectional manner is involved
mainly in fructose uptake across the basolateral membrane of
the intestinal and renal epithelial cells (14) after apical trans-
port mediated by GLUT5, fructose is transported across the
basolateral membrane by GLUT2 (Fig. 2). Kidney GLUT5 is
therefore remarkably responsive to its substrate fructose. The
response of GLUT5 is quite specific; GLUT2 expression is
similar among fructose, glucose and non-metabolizable glucose
analogs. Tissue-specific coordinated expression of glucose
transporters could play an important role in the regulation of
glucose uptake and metabolism under various nutritional and
hormonal conditions. It has long been recognized that cancer
cells have increased rates of glucose metabolism compared
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with healthy cells (15-17). A variety of mechanisms have been
proposed for the accelerated glucose use seen in growing
tumours and in transformed and malignant cells: increased
concentrations of hexokinase (18,19), decreased rates of
glucose-6-phosphatase mediated dephosphorylation (20) and
enhanced rates of glucose uptake have been noted. Moreover,
tumour cells can apparently express glucose transporters that
are not substantially expressed in the non-malignant tissue.
Renal cell carcinomas can be subclassified into clear cell
carcinomas, papillary type I and II cell carcinomas, chromo-
phobe cell carcinomas and oncocytomas.
The clear cell form of renal cell carcinoma is the most
common type of renal tumours, and the cells are characterized
histologicaly by a distinctive pale, glassy cytoplasm (21). It has
been previously suggested (21) that the clear appearance of
tumour cells results from some abnormality in the metabolism
of carbohydrate and lipids and this abnormality results in
glycogen and sterol storage.
It has been demonstrated that a series of characteristic
changes occur in the carbohydrate metabolism of renal clear
cell carcinomas: increase in glycogen synthesis, activation of
glycolysis and gluconeogenesis reduction.
The above alterations of the carbohydrate metabolism
within clear cell carcinomas are clearly distinct from those
observed in papillary cell carcinoma, chromophobe cell
carcinomas and oncocytomas (22).
The clear cell type of RCC has a typical golden colour
due to the rich lipid content of its cells: cholesterol, neutral
lipids and phospholipids are abundant (Fig. 3) (23). These
accumulate as droplets in the cytoplasm of tumour cells due
to deficient glycogenolysis and lipolysis associated with
unresponsiveness of the tumour cell adenylate cyclase to
glucagon. The lipid content is markedly similar to that of
proximal convoluted tubules.
Microscopically, the cells of cRCC type are filed with
lipids and cholesterol which are dissolved in usual histo-
logical preparations, creating a clear cytoplasm surrounded
by a distinct cell membrane. These neutral lipids can be
identified in unfixed material using Oil Red 0 and Sudan III
and IV reaction. The phospholipids may be identified with
the same stains. Glycogen can be identified using periodic
acid-Schiff (PAS) or Best stain.
Previous studies demonstrated high glycolytic rates in
renal clear cell carcinoma samples showing a series of
characteristic changes occurring in the carbohydrate
metabolism, however, the GLUT5 protein has not been
implicated in this setting. The utility of fructose and function
of GLUT5 in cRCC was shown to be uncertain. The GLUT5
is expressed in only a limited number of tissues seemingly
capable of preferentially metabolizing fructose, and exist in
two major categories of transcriptional and/or post-
transcriptional regulation of GLUT5. In the apical membrane
of polarized cells (e.g., kidney cells) GLUT5 is acutely and
specifically regulated by its own substrate, whereas in the
other tissues fructose seems to have no acute effect.
Because the GLUT5 transporter is commonly found in
tissues that metabolize fructose, we hypothesized that cRCC
may be capable of utilizing fructose as an energy substrate,
and GLUT5 to collaborate in glycogen and cholesterol storage.
Material and methods
Patients and tumour samples. The clinical and pathological
data of patients who were diagnosed with RCC and underwent
surgery at the Department of Urology of Modelo Hospital, A
Coruña, Spain, from 1996 to 2007 were reviewed. The study
group consisted of 80 patients whose original pathological
specimens were available for evaluation. The average age of
the study population was 62 years being 66% male and 34%
female. The histological study included 57 clear renal cell
carcinomas, 6 papillary renal cell carcinomas, 15 chromophobe
renal cell carcinomas and 2 samples with unknown histological
type.
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Table I. Major sites of expression of the family glucose transporters (GLUT1-5).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Name Tissue distribution Role and important features Refs.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
GLUT1 Placenta, brain, blood-tissue barrier, Basal glucose uptake in many cells (80-84)
muscle and adipose tissue, kidney kinetically asymmetric
GLUT2 Kidney (proximal tubule) High capacity, low affinity transporter (4,80)
liver, pancreatic ß-cell, important for glucose sensing in ß-cell
small intestine (basolateral membranes) transepithelial glucose and fructose transport
GLUT3 Brain, nerve cells, Neural transporter (80,85-87)
small intestine, kidney role in small intestine unclear
GLUT4 Muscle and adipose tissue Expressed only in tissue that exhibit acute (88-100)
insulin-stimulated glucose transport
Heart translocates to plasma membrane in
response to insulin
GLUT5 Jejunum (apical membranes), kidney, Physiological role in fructose adsorption (26-31,101)
muscle and adipose tissue at low levels
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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The Institutional Review Board of Modelo Hospital (A
Coruña, Spain) approved the retrospective review of the
medical records and the use of archived tumour specimens.
Tissue microarray generation. All archival tissue samples
were routinely fixed in formalin and embedded in paraffin.
Representative tissue areas were marked on standard haemato-
xylin and eosin sections, punched out of the paraffin block
using 2.0-mm punch, and inserted in a recipient paraffin block,
to produce a 6x8 array of 48 cases. In addition, one normal
cerebellum tissue was inserted as a negative control. When it
was possible triplicate cores per specimen were arrayed on
a recipient paraffin block in order to decrease the error
introduced by sampling and to minimize the impact of tissue
during processing. Sections (4 μm) were cut from the com-
pleted array blocks and transferred to silanized glass slides.
Immunohistochemistry. The working dilution was determined
using positive controls, as indicated in the literature. For
GLUT1, oesophagus was used; for GLUT2, liver was used;
for GLUT3, placenta was used, for GLUT4, heart was used
and for GLUT5, small intestine was used. Additional sections,
running in parallel but with omission of the primary antibody
served as negative controls.
The tissue sections were deparaffinized by incubation in
xylene and rehydrated in a graded series of ethanol and water
solutions. The antigen was retrieved with 0.01 M citrate
buffer (pH 6.0) by heating the samples in a microwave vacuum
histoprocessor (2100 Retriever™, PickCell Laboratories) at
a controlled final temperature of 121˚C for 15 min. The
primary antibodies were diluted in Dako antibody diluent
(DakoCytomation) with background-reducing components
and were used at the followings dilutions: GLUT1-2 (1:50,
Abcam), GLUT3 (1:25, Abcam), GLUT4-5 (1:250, Abcam).
The primary antibodies were incubated at room temperature
for 30 min and detected using the Dako EnVision system
and diaminobenzidine according to the manufacturer's
instructions.
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Figure 1. Many glucose transporters (GLUT1-5) are expressed in different
human organs.
Figure 2. Among the GLUT family members able to transport fructose,
GLUT5 is the sole transporter specific for fructose with no ability to trans-
port glucose or galactose. The second major fructose transporter is GLUT2,
a low-affinity transporter that is also capable of recognizing glucose and
galactose.
Figure 3. (A) The clear cell type of RCC is typically golden due to the rich
glycogen and lipid content of its cells: cholesterol, neutral lipids and
phospholipids. (B) Renal cell carcinoma stained with PAS, a dense granular
deposition in the cytoplasm of cells (short arrow) and larger cells (long
arrow) due to glycogen are visible (PAS x400). (C) Stained for cytoplasmic
fatty deposits are seen as globules of different diameters. (Oil Red x400).
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Semi-quantification of antibody staining. The immuno-
reactivity score (IRS) was evaluated, following other groups,
by multiplying the percentage of positive cells (PP %) and
the staining intensity (SI). First, the PP % was scored as 0 for
<1%, 1 for 1-24%, 2 for 25-49%, 3 for 50-74% and 4 for
≥75%. Second, the SI was scored as 1 for weak, 2 for medium
and 3 for intense staining. Each slide was carefully examined
in the area of the tumour that contained the greatest fraction
of positively stained cancer cells.
Statistical analysis. Data are expressed as the mean ±
standard deviation (SD). The statistical significance of
differences found was evaluated at the 95% confidence level
by non-parametric statistics, Mann-Whitney U and Kruskal-
Wallis tests, p-values <0.05 were considered the cut-off point
for significance. The statistical analyses were performed
using commercially available software (SPSS 17.0 for
Windows).
Results
Tumour tissue samples from 80 RCC patients were analysed
by immunohistochemistry for expression of different GLUT
isoform (Figs. 4-6). Pathological characteristic of RCC patients
are detailed on Table II.
GLUT1 showed membranous staining in red blood cells
in the controls (Fig. 4A). Positive but weaker staining was
also observed in 38 of 80 (47.5%) RCC samples where
GLUT1 staining was observed in the plasmatic membrane
and cytoplasm. Tubular epithelium, glomerulus and interstice
were negative for GLUT1 staining. There was no correlation
between GLUT1 staining and the pathological parameters
considered for review as grade of differentiation, pelvis
invasion and breaking capsule (Table II).
GLUT2 was detected as strong reaction in cell membrane
in 58 of 80 (72.5%) RCC samples (Fig. 4B). Cytoplasm
reaction could be observed with moderate intensity in 27.5%
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Figure 4. (A) GLUT1 immunostaining in RCC. The tubular epithelium,
glomerulus and interstices are negative (x40). Intravascular erythrocytes are
positive. (B) GLUT2 immunostaining in RCC. Moderate cytoplasmic
positivity in 40% of tumour cells (x50).
Figure 5. GLUT4 immunostaining in RCC. Light cytoplasmic positivity in
10% of tumour cells (x50).
Figure 6. GLUT5 immunostaining. (A) Normal kidney with intense positivity
in the apical pole of the tubular epithelium. The glomerulus, the interstices
and the vascular endothelium are negative (x40). (B) Intense membrane
positivity in most tumour cells (x50). (C) Intense cytoplasmic positivity in
most tumour cells (x50).
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of RCC samples. No significant correlation between the
histological parameters studied and the expression of GLUT2
was seen (Table II).
GLUT3 was detected in 30 of 80 (37.6%) RCC samples
showing weak cell membrane reaction and granular cyto-
plasmic staining. No significant correlation between the
histological parameters studied and the expression of GLUT3
was seen (Table II).
GLUT4 was detected in a weak cytoplasmic pattern in
45 of 80 (56.3%) RCC samples (Fig. 5). Patients who were
classified as T4 showed statistical significance of p=0.029,
and higher GLUT4 expression than the others (Table II).
In normal kidney, we also observed GLUT4 stain on the
apical pole of tubular epithelium. Vascular endothelium,
glomerulus and interstice were negative. GLUT5 showed
high intensity in the membrane and cytoplasm of tumoural
cells in 46 of 80 (57.6%) RCC samples (Fig. 6B and C). A
significant positive (p=0.024) correlation was found between
moderately differentiate RCC tumour tissues and GLUT5.
Patients who had pelvis invasion also showed significant
(p=0.039) higher GLUT5 expression than the others. A
significant positive (p=0.019). correlation was observed
between GLUT5 expression and patients who had breaking
capsule. Related to histological type we found that GLUT5
expression was significant higher in clear RCC (p=0.001)
(Table II).
Discussion
In the kidney, GLUT5 mRNA was shown abundant in the
cytosol, and protein is present in the apical plasma mem-
brane of S3 proximal tubule cells (24), where GLUT5 may
potentially recapture fructose lost from glomerular filtration.
Its expression is also inducible by the fructose diet (25) after
the small intestine; the kidney expresses the most GLUT5 in
human, rat and rabbit (26-31). Regulation of GLUT5 was first
discovered in the intestine and testis, but also in the kidney,
skeletal muscle, fat tissue and brain. Modest to significant
levels of GLUT5 mRNA and/or protein have now been demon-
strated in kidney, fat, skeletal muscle and brain (32-38).
GLUT5 expression levels and fructose uptake rates are also
significantly affected by diabetes, hypertension, obesity and
inflammation (metabolic syndrome), and seem to be induced
during carcinogenesis, particularly in the mammary glands
(39).
The primary metabolic characteristic of malignant cells is
an increased uptake of glucose and its anaerobic metabolism,
and available evidence indicates that the mechanism by which
cancer cells increase their ability to take up glucose involves
the selective overexpression of glucose-transporters (40).
It is currently accepted that the increase in glucose uptake
by malignant cells is associated with the overexpression of
GLUTs.
Overexpression of the facilitative glucose-transporter has
been observed for a wide range of human cancers (41-58)
with the degree of overexpression generally being inversely
correlated with prognosis. The mechanisms by which GLUTs
promote malignant cellular behaviour have focused on factors
inducing its expression, such as local hypoxia (37), oncogenes
such as Ras, Scr (15) or Myc (38).
In human renal cell carcinoma immunohistochemical
staining GLUT1 was found in 73.3% of tumour specimens
analyzed, and in the 84.6% of clear cell subtype (58), hetero-
geneous expression of GLUT1 was observed in tumour cell
mass: some tumour cells were positive for GLUT1, while
other cells were not (43). GLUT4 staining was not recognized
in either tumour or normal tissues (58). Using RT-PCR in
kidney tumours, it has been showed that histopathological
types are characterized by specific patterns of GLUT
expression (59).
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Table II. Relationship between GLUT5 expression and patho-
logical significance of RCC.
–––––––––––––––––––––––––––––––––––––––––––––––––
Pathological Patients no. GLUT5 range/
parameter n=80 p-value
–––––––––––––––––––––––––––––––––––––––––––––––––
Differentiation degree
(Fuhrman grade)
Well 15 44.81/0.024
Moderate 45
Poor 16
Undifferentiated 4
Pelvis invasion
Yes 9 54.56/0.039
No 66
Undetermined 5
Breaking capsule
Yes 12 54.75/0.019
No 64
Undetermined 4
Tumour depth
1 63 56.63/0.437
2 4
3 12
4 1
Histology type
Clear cell 57 46.98/0.001
Papillary 6
Chromophobe 15
Undetermined 2
Tumour localization
Right 40 40.13/0.959
Left 39
Undetermined 1
Veins invasion
Yes 9 63.00/0.312
No 67
Undetermined 4
–––––––––––––––––––––––––––––––––––––––––––––––––
Ranges are median.
–––––––––––––––––––––––––––––––––––––––––––––––––
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Fructose is now such an important component of human
diets that increasing attention is being focused on the fructose
transporter GLUT5. Fructose is transported passively across
membranes by a member of the facilitative glucose trans-
porter (GLUT) family, named GLUT5 (60-64) and it is the
sole transporter specific for fructose with no ability to transport
glucose or galactose. The low intracellular fructose concen-
tration is possible because fructose is metabolized and signi-
ficantly contributes to glycogenolysis in muscle or lipogenesis
in adipocytes (63,65).
The products of fructose metabolism are glycogen and
de novo lipogenesis of fatty acids and eventual synthesis of
endogenous triglyceride can be divided into two main phases:
the first phase is the synthesis of the trioses, DHAP and GA;
the second phase is the subsequent metabolism of these
trioses in either in the gluconeogenic pathway for glycogen
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Figure 7. Steps in fructose metabolism.
Figure 8. Surrounding a capillary (black arrow) there are tumour cells with
abundant fat vacuoles (white stars). Other cells, probably in apoptosis (white
arrow) contain lysosomes and grains of glycogen (x2800).
Figure 9. One tumour cell observed at higher magnification with electron
microscopy showing clearly the grains of glycogen (x3500).
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replenishment and/or the complete metabolism in the fructo-
lytic pathway to pyruvate, which enters the Krebs cycles, is
converted to citrate and subsequently directed toward de novo
synthesis of the free fatty acid palmitate (66).
The first step in the metabolism of fructose is the phospho-
rylation of fructose by fructokinase and aldolase to yield
fructose and respectively dihydroxyacetone (DHAP) glycer-
aldehyde (GA) and glyceraldehyde-3phosphate (GA-3-P)
(Fig. 7).
The resultant GA then undergoes phosphorylation to
GA-3-P. Increased concentrations of DHAP and GA-3-P
drive the gluconeogenic pathway toward glucose-6-phospate
(G-6-P), glucose-1-phosphate (G-1-P) and glycogen (Fig. 7).
It appears that fructose is a better substrate for glycogen
synthesis than glucose and that glycogen replenishment takes
precedence over triglyceride synthesis.
Once organ glycogen is replenished, the intermediates of
fructose metabolism are primarily directed toward triglyceride
synthesis (Fig. 7-9).
In human adipocytes, a study demonstrated, hypoxia
increases GLUT5 expression (9-fold) (64). Because hypoxia
becomes more common during renal cell carcinoma (RCC)
progression, it can be one of the factors leading to increases
in GLUT5 expression in clear renal cell carcinoma (cRCC).
Along with GLUT5, the mRNA expression of key gluco-
neogenic enzymes, glucose-6-phosphatase (G-6-Pase) and
fructose-1, 6-bisphosphatase (FBPase), increased significantly
in clear renal cell carcinoma, suggesting a link between
gluconeogenesis on the one hand and fructose transport as
well as intracellular fructose on the other. FBPase activity is
indirectly regulated by cAMP, which increases in vivo in the
kidney epithelia exposed to fructose compared with those
exposed to glucose. It has been demonstrated in vivo that
cAMP modulates fructose transport induced by fructose
without affecting GLUT5 mRNA abundance (65), whereas
in vitro, cAMP affects GLUT5 mRNA expression levels and
is involved in GLUT5 regulation in kidney epithelia (67-70).
GLUT5 mRNA and protein expression are affected by the
development of tumours in certain organ systems. In general,
oncogene-transformed cell that portray cancerous character-
istics will also exhibit an increase in glucose transport by
overexpression specifically sugar transporters like GLUT1 in
breast cancer (71), colorectal (57) and like GLUT3 in lung
cancer (72,73). Although GLUT5 is poorly expressed in
normal kidney epithelial cells, the renal cell carcinoma tissue
posses high amount of GLUT5 mRNA and protein and
exhibit high rates of fructose transporter. This finding was
confirmed a number of times in later studies. Screening of
the GLUT5 in malignant vs. normal human tissues and cells
showed that GLUT5 was highly overexpressed in 27% of
cancerous tissues tested, including many type of human
tumours (74).
We have also shown here, in a panel of 80 samples from
RCC patients, significant higher expression of GLUT5 isoform
was also found in RCC cells vs. normal kidney. In addition,
GLUT5 staining appeared stronger in clear cell subtype than
in others RCC histology types. These data suggest a main
role for GLUT5 in glucose/fructose uptake in RCC tumour
cells. In addition GLUT5 expression was correlated with
clinicopathological features of advanced RCC.
In conclusion, by means of immunohistochemistry we
have confirmed GLUT5 expression in clear renal cell carci-
noma (cRCC), significantly in high Fuhrman degree, whereas
GLUT1-4 expression was modest. The extensive expression
of the glucose transporters, and the fact that in most of the
cRCC overexpressing GLUT5 the rate of fructose uptake is
exacerbated, indicate that fructose may be a preferred sub-
strate providing energy required for the growth and prolifer-
ations of renal cell carcinoma of clear cell type. This increase
of GLUT5 could indicate preferential utilization of fructose
by renal cancer cells. The link between fructose and clear cell
type of RCC was obvious. Interestingly, it was observed that
cancer cells maintain a high rate of glycolysis even in presence
of oxygen, a phenomenon called the Warburg effect (75,76).
One of the major regulatory steps in glycolysis involves
conversion of fructose 6-phosphate to fructose-1, 6-bisphos-
phate by phosphofructokinase-1 (PFK-1). The activity of
PFK-1 is allosterically controlled by fructose-2, 6-bisphosphate
and the product of the enzymatic activity of a dual kinase/
phosphatase family of enzymes (PFKFB1-4) that is also
increased in a significant number of tumour types (77).
Fructose is known to stimulate the intestinal expression of
PFKFB1 (78), but it is not known whether fructose leads to
increased levels of fructose 2, 6-bisphosphate. However, it is
clear hat the rate of glycolysis can be stimulated by fructose
because its entrance into glycolysis skips the two main
regulatory enzymes (glucokinase and PFK-1) (79). Either the
presence of high levels of GLUT5 protein leads to a greater
use of fructose in neoplastic cells, in clear renal cell
carcinoma or increased usage of fructose leads to a higher
abundance of GLUT5 expression. The role of fructose in
cRCC is clearly observed.
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